# dotcool

Leading the Way in Patient-Centric Medication Care


- Canonical URL: https://wefunder.com/dotcool
- Entity ID: wefunder:company:140290
- Last updated: 2026-06-11T23:53:47Z
- Generated at: 2026-06-12T04:01:47Z

## Quick facts
- Founders are patients themselves solving a problem for millions of fellow patients
- Temperature monitors and protectors for medications like insulin and other injections
- Building up on success of prior venture, reaching 10k patients worldwide
- First community-acclaimed product and app launched in the US and Europe already
- 3 patents filed to secure innovation, strengthen market edge, and showcase pioneering commitment.
- Dedicated team with a decade of experience in health tech and patient-centered product development.
- Strong advisory team of industry veterans and problem solvers in biotech and healthcare management.
- Serving a multibillion $ market with a compound annual growth rate (CAGR) of 10.3 %

## Active fundraises
- wefunder:fundraise:92972: 4(a)(6) open (USD)

## Story
Executive Summary:Safeguarding the integrity of temperature-sensitive medications is more than a need—it's a lifeline for many of us. At dotcool, we're bridging the critical gap with innovative, user-friendly, and affordable solutions.From daily monitoring to travel assurance, our products are designed for those who can't afford to take chances with their medications. Backed by a team with personal stakes and professional prowess, and building on the success of our first venture in this field, we invite you to invest and partner with us. Together, we can make sure that medications remain safe and effective for everyone.Every day, millions of patients rely on temperature-sensitive medications such as insulin, EpiPens, GLP-1 injections for diabetes and obesity, certain hormone therapies, biologic drugs like Humira, and multiple sclerosis treatments like Copaxone for their well-being and quality of life [1]. But safeguarding these essential medications from temperature fluctuations, which can diminish their effectiveness or even render them unsafe, remains a challenge. This is not just a matter of convenience—it's about safety, health, and peace of mind [2].Our products combine advanced technology with great user experience, for monitoring, or monitoring and protection:1. dotcool mini: Compact, affordable, app-enabled temperature monitor. Already available to order on our webshop: https://shopus.dotcool.co/products/dotcool-miniContinuously monitor medications' temperatureAccurate, compact and easy to use200+ medications supportedAlerts on your phone in case of problems (Bluetooth)See the full picture of temperature history (click here to see a short product video. 1:47min)2. dotcool box: Protective, connected storage container.Protects medications for up to 48h in case of cooling failureRemotely monitor medications' temperature (Wifi)Passive temperature regulation using phase change materialsPortable and rugged design is suitable for travels (click here for more details)With our products, you can keep your medications in the right conditions. Our devices are designed to meet a variety of needs:Everyday use: Regularly track your medications whether they’re in your car, on your bedside table, or when being outdoors, ensuring they remain at a safe temperature.Travelling: Perfect for those carrying temperature-sensitive medications during their travels, providing peace of mind by ensuring the medications remain safe throughout transit.Fridge storage: our devices stand out by ensuring temperatures remain steady and appropriate. Especially if electricity shortages are frequent.In our first phase from 2023 to 2025, we will operate on a direct to consumer sales model. The wireless monitor is priced at $39, while the connected box comes in at $249.Starting 2025, as we roll into phase 2, we’ll introduce a subscription for premium features (4.99$/month) that add even more value to users.As we look forward, our vision is to expand our product line, enhance our software capabilities, and build a community of empowered patients. We aim to be the go-to solution for everyone needing to maintain the integrity of their temperature-sensitive medications.The biologic injections market is experiencing rapid growth at a rate of 10.3% CAGR, with top-selling drugs like Humira, Ozempic, and Mounjaro leading the way [3]. These treatments are game-changers for many, but they also underscore the critical need for reliable temperature monitoring. These drugs currently make up more than 50% of the pharmaceutical industry's income, and this number is on the rise [4]. Their increasing share of the market underscores their effectiveness and growing preference in medical treatments. With the continuing trend, it's evident that biologics will further solidify their position in the industry and the number of patients using them and relying on them will further grow [5].Considering both the USA and Europe, the total addressable market for our products is estimated at $6B/year. With 16M people relying on temperature-sensitive medications in the USA and 19M in Europe, considering both direct sales and future subscription services.This isn’t our first venture in this field. We’ve previously introduced MedAngel, a venture that garnered praise and trust from the medical community and patients alike. We’re building on that legacy with dotcool.Our community is the driving force behind everything we do. We never miss an opportunity for in-person interactions with our users, recognizing the unparalleled insights such encounters provide. By conducting usability tests and listening to their feedback, we gain a deeper understanding of their needs and preferences. These insights are then channeled directly into our product development, ensuring that our solutions are both innovative and user-centric.For example: it is our users from Florida and Texas who brought to our attention how they have to evacuate their homes during hurricane season and what exactly what we should change in the design of dotcool box to be more suitable this particular situation.Regarding intellectual property, we've invested heavily to ensure our innovations don't infringe on existing rights. Before development, we extensively researched to ensure our products respected all current patents. By taking this step, we have successfully secured our freedom to operate without legal disputes.Having established our position, we decided to further fortify our competitive advantage by filing three separate patent applications. These filings are strategic moves designed to protect our innovative processes and technologies, securing our leading edge in the market and showcasing our commitment to pioneering advancements in the field.Our team is a blend of personal passion and professional prowess:Amin Zayani: Amin combines his personal experience living with diabetes, his background in solar energy and Internet of Things (IoT), and his award-winning entrepreneurial acumen to drive the mission of dotcool. His significant achievements include winning the prestigious Novo Nordisk Patient Entrepreneur Award in 2017, further underscoring his commitment and contribution to innovating patient-centered healthcare solutions.Robert Bialas: With over 10 years of experience leading research, development, and production at a major German medtech firm, Robert's expertise is far-reaching. His impressive blend of engineering knowledge and industry insights allowed him to contribute to engineering at dotcool. His leadership and dedication continue to push the boundaries of patient-centric solutions.Lena Rieger: Lena's background is in creating digital products and campaigns in the non-profit and climate sectors. Known for her user-centered approach and her commitment to positive change, Lena skillfully translates complex issues into intuitive design solutions.Our advisory team are industry veterans. Through their unparalleled knowledge and years of experience, they play a pivotal role in our success, steering us adeptly through challenges and opportunities alike:Prof. Lutz Heinemann: Prof. Heinemann is a prominent figure in the field of diabetes research. He established the Profil Institutes in both Germany and the United States, key institutions dedicated to the clinical trials of diabetes treatments. He has made significant contributions to clinical diabetes research and innovation, focusing on insulin therapy and glucose monitoring.Heidi Rataj: Heidi is the program director of Design+ Strategy at the UCSD Health. She is committed to resolving complex healthcare issues through collaboration and innovative digital tool design. Her unique expertise, sharpened in the entertainment industry, drives her work on chronic diseases, diabetes, and mental healthBastian Hauck: Bastian is a renowned diabetes advocate. He founded #dedoc°, a global digital platform promoting exchange and support among those living with diabetes. Under his guidance, #dedoc° has also launched the world's largest scholarship program for diabetes advocates, revolutionizing diabetes community engagement and personal health management.The funds we raise will be allocated as follows:40% towards product development, refining dotcool mini and our app. Also it will contribute to further development of dotcool box.40% for marketing and commercial efforts, ensuring our reach through online channels and in-person events.20% will be channeled into IP protection and administrative costs.We are rewarding WeFunder investors with dotcool products in three levels:500$: We will send you one dotcool mini device (worth 39$).1000$: We will send you three dotcool mini devices (worth 117$).2500$: We will send you three dotcool mini devices AND a dotcool box when it is available (worth 366$).The very first investors (first 50,000$) will receive a convertible note with a lower cap (6M instead of 7.5M) AND one dotcool mini sensor.And we will be grateful for all your feedback and suggestions to help us make the best possible products.This is more than just an investment opportunity; it's a chance to be part of a movement.Join us as a shareholder, support a cause that safeguards health, and let's shape the future of medication safety together.Sources:1. Kane SP. The Top 300 of 2020, ClinCalc DrugStats Database, Version 2022.08. ClinCalc: https://clincalc.com/DrugStats/Top300Drugs.aspx. Updated August 24, 2022. Accessed August 8, 2023.2. Heinemann, Lutz, Katarina Braune, Alan Carter, Amin Zayani, and Laura A. Krämer. "Insulin storage: a critical reappraisal." Journal of diabetes science and technology 15, no. 1 (2021): 147-159.3. Grand View Research. "Biologics Market Size, Share & Trends Analysis Report By Source (Microbial, Mammalian), By Product (MABs, Recombinant Proteins, Antisense & RNAi), By Disease Category, By Manufacturing, By Region, And Segment Forecasts, 2023 - 2030" Grand View Research.4. Evaluate Pharma. "World Preview 2020, Outlook to 2026." Evaluate.5. Gonzalez M. "Recent Trends and Developments in Injectable Drug Formulation and Delivery." ONdrugDelivery, issue 133 (2022): 16-18.

## Team
- Amin Zayani (CEO)
- Robert Bialas (dot.COOL Group Inc.)
- Lena Rieger (UX/UI Designer)

## Q&A
- Q: Can you provide further details on your growth to date? Specifically, your plans call for 80k users and $6m revenue in 2024. How are you tracking against these goals now that we're 3 quarters through the year? Also, when do you anticipate filing form C or providing more financial details?